Scisparc Ltd
scisparc.comWhat Do They Do?
Develops cannabinoid-based drug candidates for patients with Tourette syndrome and Alzheimer’s-related agitation, and sells hemp seed oil-based products to online shoppers.
20-F for FY2025, filed Apr 29, 2026We, through our subsidiary NeuroThera, engage in clinical-stage pharmaceutical developments. Our focus is on creating and enhancing a…View ↗
Who Are Their Customers?
The company sells hemp seed oil-based products directly to customers, mainly through its brand’s online Amazon stores.
How Are They Changing?
Pain program outlicensed
The older report included a cannabinoid candidate for pain in its development portfolio; the latest report says the company licensed the program to Polyrizon and no longer develops it.
20-F for FY2022, filed May 1, 2023 20-F for FY2025, filed Apr 29, 2026On August 13, 2024, we entered into the license agreement to outlicense our SCI-160 program, which was a novel pharmaceutical preparation…View ↗
Who Do They Compete With?
Competes with Unimed Pharmaceuticals, AbbVie, SVC Pharma, Akorn, Meda, GW, Zynerba, Skye, Corbus Pharmaceuticals Holdings, Synendos, and Inversago Pharma
20-F for FY2025, filed Apr 29, 2026The first THC-based pharmaceutical, a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a…View ↗
Loading...
